---
title: "Pliant Therapeutics | 8-K: FY2026 Q1 Revenue: USD 0"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/285989685.md"
datetime: "2026-05-11T20:13:54.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/285989685.md)
  - [en](https://longbridge.com/en/news/285989685.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/285989685.md)
generator: "portal-rs"
---

# Pliant Therapeutics | 8-K: FY2026 Q1 Revenue: USD 0

Revenue: As of FY2026 Q1, the actual value is USD 0.

EPS: As of FY2026 Q1, the actual value is USD -0.32, beating the estimate of USD -0.356.

EBIT: As of FY2026 Q1, the actual value is USD -21.77 M.

#### Financial Performance for the Three Months Ended March 31, 2026

-   **Research and Development (R&D) Expenses:** Pliant Therapeutics, Inc. reported R&D expenses of - $13.6 million for the first quarter of 2026, a decrease compared to - $43.4 million in the prior-year quarter, primarily due to the completion of close-out activities for the BEACON-IPF study in 2025 and reduced personnel-related expenses from decreased headcount.
-   **General and Administrative (G&A) Expenses:** G&A expenses were - $8.2 million for the first quarter of 2026, down from - $15.5 million in the prior-year quarter, mainly due to lower personnel-related expenses, including stock-based compensation, resulting from a reduced headcount.
-   **Net Loss:** The company’s net loss for the first quarter of 2026 was - $20.0 million, an improvement from a net loss of - $56.2 million in the prior-year quarter, driven by significantly lower operating expenses following the termination of bexotegrast development in IPF in 2025 and decreased personnel-related expenses.
-   **Interest and Other Income (Expense), Net:** Interest and other income (expense), net was $1.7 million in the first quarter of 2026, compared to $3.6 million in the prior-year quarter.
-   **Interest Expense:** There was no interest expense reported for the first quarter of 2026, compared to - $0.8 million in the prior-year quarter.

#### Financial Position as of March 31, 2026

-   **Cash, Cash Equivalents, and Short-Term Investments:** As of March 31, 2026, Pliant Therapeutics, Inc. held $172.4 million in cash, cash equivalents, and short-term investments, comprising $22.2 million in cash and cash equivalents and $148.7 million in short-term investments.
-   **Total Current Assets:** Total current assets were $174.9 million as of March 31, 2026, compared to $196.4 million as of December 31, 2025.
-   **Total Assets:** Total assets were $202.6 million as of March 31, 2026, down from $225.2 million as of December 31, 2025.
-   **Total Current Liabilities:** Total current liabilities were $10.4 million as of March 31, 2026, compared to $16.4 million as of December 31, 2025.
-   **Total Liabilities:** Total liabilities were $37.4 million as of March 31, 2026, compared to $44.0 million as of December 31, 2025.
-   **Total Stockholders’ Equity:** Total stockholders’ equity was $165.2 million as of March 31, 2026, compared to $181.2 million as of December 31, 2025.

#### Operational Highlights and Outlook

-   **Operational Metrics:** Pliant Therapeutics, Inc. initiated FORTIFY, a Phase 1b indication expansion trial for PLN-101095, ahead of schedule, with the first participant dosed in April 2026. The company continues to advance its proprietary integrin-targeted delivery platform with ongoing preclinical proof-of-concept studies.
-   **Financial Outlook:** Pliant Therapeutics, Inc. expects its $172.4 million in cash, cash equivalents, and short-term investments as of March 31, 2026, to be sufficient to fund operations into the second half of 2028.

### Related Stocks

- [PLRX.US](https://longbridge.com/en/quote/PLRX.US.md)

## Related News & Research

- [Annaly Capital declares Q3 2026 dividend of $0.75 per share](https://longbridge.com/en/news/298499808.md)
- [HPS/PayMedix Named a 2026 Best and Brightest Company to Work For](https://longbridge.com/en/news/298358823.md)
- [Essex Property Trust declares Q3 2026 dividend of R$ 0.89 per unit](https://longbridge.com/en/news/298322539.md)
- [Acteos delays H1 2026 results release to Oct. 28](https://longbridge.com/en/news/298618428.md)
- [Ecosuntek adds Q3 KPI update to 2026 corporate events calendar](https://longbridge.com/en/news/298712114.md)

---
> **Disclaimer: This article is for reference only and does not constitute any investment advice.**